Back to search

University of British Columbia

Tailoring allosteric modulators of NMDA receptors and GABA-A receptors for neurological disorders

Abstract

dc:description

Both N-methyl-D-aspartate (NMDA) receptor, one of the subtypes of ionotropic glutamatergic receptors at the vast majority of excitatory synapses, and the type A γ-aminobutyric acid receptor (GABAAR), the principal ionotropic GABARs at the inhibitory GABAergic synapses play essential roles in regulating neuronal activities in the mammalian central nervous system (CNS). Their dysfunctions contribute to the pathogenesis of many neurological disorders. Overactivation of NMDAR-mediated excitotoxicity is a common cause of many neurodegenerative diseases including stroke. There are two prevalent theories, the ‘NMDAR subtype hypothesis’ that proposes that activating GluN2A-containing NMDAR promotes neuronal survival, whereas activating GluN2B-containing NMDARs leads to neuronal death, and the ‘NMDAR location hypothesis’ that suggests that activating synaptic, primarily GluN2A-containing NMDARs favors neuronal survival while activating extrasynaptic, predominantly GluN2B-containing NMDARs induces neuronal death. Since both hypotheses support allosteric modulators that potentiate GluN2A function and inhibit GluN2B function may have promising potentials as a new and more effective class of neuroprotective therapy for stroke, we performed computer-aided virtual screening and in-silico drug design to discover a lead compound 813 that functions as an NMDAR dual allosteric modulator (Ndam) that potentiates GluN1/GluN2A and at the same time inhibits GluN1/GluN2B. We further optimized Ndam813 and thereby developed two more efficacious compounds, Ndam830 and Ndam844. Ndam830 protected cortical neurons from NMDA-induced excitotoxicity and H2O2-induced oxidative stress, and also reduced ischemia-induced infarct volume, and promoted behavioral recoveries in rat MCAo models. Thus, our results strongly suggest that Ndam830 by promoting synaptic/GluN2A-containing NMDAR mediated cell survival signaling and inhibiting extrasynaptic/GluN2B-containing receptor mediated cell death signaling, is a novel neuroprotective stroke therapeutic. Ndam844 is a potent pan-NMDAR potentiator that can potentially treat NMDAR hypofunction related disorders. Apart from NMDARs, dysfunction of GABAARs is also implicated in various neurological conditions. Using electrophysiological and biochemical methods, we characterized the functional alterations of two de novo GABAAR variants T292S and T292I identified in patients with epileptic encephalopathy (EE) and developmental delay. Moreover, we found clinically approved allosteric modulators of GABAAR that may treat the patients carrying the variants. In summary, allosteric modulators of both NMDARs and GABAAR showed great therapeutic potential for neurological disorders.

Degree

thesis:*
Name thesis:degree_name
Doctor of Philosophy - PhD
Level thesis:degree_level
doctoral
Discipline thesis:degree_discipline
Neuroscience
Grantor dc:publisher
University of British Columbia
Year dc:date
2023

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Chen, Wenlin
Contributors dc:contributor
  • Wang, Yu Tian

Rights

dc:rights
Statement dc:rights
  • Attribution-ShareAlike 4.0 International
Language dc:language
eng

Identifiers

dc:identifier.*
Handle dc:identifier
http://hdl.handle.net/2429/83909

Chain of custody

source
Harvested from
University of British Columbia
Base URL
circle.library.ubc.ca/oai/request
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
related terms
citation

Chen, Wenlin. Tailoring allosteric modulators of NMDA receptors and GABA-A receptors for neurological disorders. doctoral thesis, University of British Columbia, 2023. http://hdl.handle.net/2429/83909